This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
Recruiting · NCT06853223 · Registry updated 2026-01-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction | Lung Injury, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Primary Graft Dysfunction, acute lung injury, cardiovascular disorder, ischemia reperfusion injury, lung disorder, respiratory system disorder, vascular disorder | Recruiting | Phase 2 | 2026-01-20 | NCT06853223 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 791 |
| University of California, San Francisco | 637 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Francisco | San Francisco | United States | 294 |